Herpes zoster virus of shingles
About us We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Read morePress releases
- GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma
- Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
- ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection
Tweets from GSK
-
GSK @GSK
TB claimed 1.6 million lives in 2017, according to @WHO. Watch to find out how our scientists are working with others to help fight one of the world’s biggest killers #WorldTBDay
about 14 hours ago -
GSK @GSK
Great read from @Telegraph on progress needed to #EndTB: gsk.to/2Fv9LT2 New @TheLancet Commission sets out targets to end TB within the next 25 years. On #WorldTBDay this Sun, we will speak on the science happening to develop potential new treatments and a vaccine.
about 2 days ago
-
GSK @GSK
#MEDIA – further positive data from the DREAMM-1 study of patients with relapsed/refractory multiple myeloma has been published in the Blood Cancer Journal.
about 2 days ago
